Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.48 |
| ▸ | CTSL | P07711 | 3/20 | 0.48 |
| ▸ | CTSS | P25774 | 3/20 | 0.48 |
| ▸ | CTSB | P07858 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | REN | P00797 | 2/20 | 0.43 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.43 |
| ▸ | MAP1LC3A | Q9H492 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5557583 | 0.98 | CTSK (0.50) | CTSKCTSLCTSSCTSBGAA | |
| SCHEMBL16316463 | 0.87 | CTSS (0.50) | CTSKCTSLCTSSCTSBGAA | |
| SCHEMBL5551719 | 0.82 | CTSK (0.48) | CTSKCTSLCTSSCTSBGAA | |
| SCHEMBL5555584 | 0.81 | CTSK (0.58) | CTSKCTSSKMT2ARENAAK1 | |
| SCHEMBL5556499 | 0.79 | CTSS (0.56) | CTSKCTSLCTSSCTSBMEN1 | |
| SCHEMBL7513684 | 0.76 | CTSK (0.51) | CTSKCTSLCTSSCTSBGAA | |
| SCHEMBL25286879 | 0.75 | CTSK (0.66) | CTSKCTSLCTSSCTSBGAA | |
| SCHEMBL27350811 | 0.74 | CTSL (0.68) | CTSKCTSLCTSSCTSBGAA | |
| SCHEMBL7392267 | 0.74 | CTSL (0.68) | CTSKCTSLCTSSCTSBGAA | |
| SCHEMBL4576781 | 0.74 | CTSL (0.68) | CTSKCTSLCTSSCTSBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070014721-A1 | Hydrazide conjugates as imaging agents | LANTHEUS MEDICAL IMAGING, INC. | 2007-01-18 | — | — | US | disclosed |
| US-20070014721-A1 | Hydrazide conjugates as imaging agents | LANTHEUS MEDICAL IMAGING, INC. | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070014721-A1 | Hydrazide conjugates as imaging agents | CA14, CA13, CA1 | CTSK 1070/4885CTSL 2354/4885CTSS 1532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.